Oncotype DX AR-V7 Nucleus Detect test now covered by Medicare for your mCRPC patients
In mCRPC, know when it's time to shift away from AR-targeted therapy. Direct your mCRPC patients toward the right course of treatment.
When Amy was diagnosed with breast cancer, she was scared. Her Oncotype DX Breast DCIS Score result made her feel in control.
How much do ineffective cancer treatments cost the healthcare system? In the US alone, Oncotype IQ tests have saved more than $3.5 billion.
The Eighth Edition AJCC Staging Manual is now effect, and it has changed staging for T1-2 N0 M0 breast cancer patients.
Latest TAILORx Data
The landmark TAILORx results provide definitive answers on which early stage ER+, HER2-, N0 breast cancer patients can benefit from chemotherapy.
Sign Up for Our Healthcare Professional Updates